Paragon Bioservices Hires Kevin Sly As SVP Marketing & Commercial Strategy

BALTIMORE, Oct. 29, 2015 /PRNewswire/ -- Paragon Bioservices, Inc., a leading contract development & manufacturing organization (CDMO), announced today the appointment of Kevin Sly to the position of Senior Vice President Marketing & Commercial Strategy, where he will lead the development and execution of the company's commercial strategy, marketing, sales, business development and account management activities.

Mr. Sly brings to Paragon over 30 years of highly-focused, hands-on business experience in the pharmaceutical, biomedical and biotechnology industries. His focus has primarily been Strategic Marketing & Business Development, from leading the efforts in pharmaceutical technology licensing and product development (including Phase IIII development and commercial manufacturing), to the development of business strategy and strategic commercial development for commercializing pharmaceutical drug delivery systems, repositioned drug candidates, human therapeutics utilizing bacteriophage, and other pharmaceutical and biotech therapies. In his most recent position at Aeras, Mr. Sly, as Vice President Business & Corporate Development, led all business and corporate development efforts, including building a CDMO business initiative to leverage technical capabilities and excess capacities, focusing on pre-clinical and Phase 1&2 GMP services. He developed and drove the marketing and business plans that delivered significant growth over 4 years, culminating in the successful sale of the assets and operations to a prominent international commercial CMO.

"We are pleased to welcome Kevin to Paragon's leadership team. Kevin brings a proven track record of developing, implementing and executing commercial growth strategy. He knows what it takes to grow an organization and will be a great asset to Paragon," said Pete Buzy, Paragon's President & CFO.

About Paragon Bioservices, Inc.
Founded in 1990, Paragon Bioservices is a contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticalsincluding the production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon's cGMP space includes microbial and mammalian suites, fill-finish and fully-segregated virus facilities.

Media Contact
Dr. Philip Wills
PH: (410) 975-4050

Logo - http://photos.prnewswire.com/prnh/20141124/160644LOGO

Suggested Articles

The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.